Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. JAMA. 2014;312(14):1429-1437.

JAMA

Oostdijk EAN, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EHR, Bernards AT, Purmer I, Brimicombe R, Bergmans D, van Tiel F, Bosch FH, Mascini E, van Griethuysen A, Bindels A, Jansz A, van Steveninck FAL, van der Zwet WC, Fijen JW, Thijsen S, de Jong R, Oudbier J, Raben A, van der Vorm E, Koeman M, Rothbarth P, Rijkeboer A, Gruteke P, Hart H, Peerbooms P, Winsser LJ, van Elsacker-Niele AW, Demmendaal K, Brandenburg A, de Smet AMGA, Bonten MJM.
PMID: 28418487
JAMA. 2017 Apr 18;317(15):1583-1584. doi: 10.1001/jama.2017.1282.

No abstract available.

Cite
Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. JAMA. 2014;312(14):1429-1437. JAMA. 2017;317(15):1583-1584doi: 10.1001/jama.2017.1282.
Oostdijk, E. A. N., Kesecioglu, J., Schultz, M. J., Visser, C. E., de Jonge, E., van Essen, E. H. R., Bernards, A. T., Purmer, I., Brimicombe, R., Bergmans, D., van Tiel, F., Bosch, F. H., Mascini, E., van Griethuysen, A., Bindels, A., Jansz, A., van Steveninck, F. A. L., van der Zwet, W. C., Fijen, J. W., Thijsen, S., de Jong, R., Oudbier, J., Raben, A., van der Vorm, E., Koeman, M., Rothbarth, P., Rijkeboer, A., Gruteke, P., Hart, H., Peerbooms, P., Winsser, L. J., van Elsacker-Niele, A. W., Demmendaal, K., Brandenburg, A., de Smet, A. M. G. A., & Bonten, M. J. M. (2017). Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. JAMA. 2014;312(14):1429-1437. JAMA, 317(15), 1583-1584. https://doi.org/10.1001/jama.2017.1282
Oostdijk, Evelien A N, et al. "Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. JAMA. 2014;312(14):1429-1437." JAMA vol. 317,15 (2017): 1583-1584. doi: https://doi.org/10.1001/jama.2017.1282
Oostdijk EAN, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EHR, Bernards AT, Purmer I, Brimicombe R, Bergmans D, van Tiel F, Bosch FH, Mascini E, van Griethuysen A, Bindels A, Jansz A, van Steveninck FAL, van der Zwet WC, Fijen JW, Thijsen S, de Jong R, Oudbier J, Raben A, van der Vorm E, Koeman M, Rothbarth P, Rijkeboer A, Gruteke P, Hart H, Peerbooms P, Winsser LJ, van Elsacker-Niele AW, Demmendaal K, Brandenburg A, de Smet AMGA, Bonten MJM. Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. JAMA. 2014;312(14):1429-1437. JAMA. 2017 Apr 18;317(15):1583-1584. doi: 10.1001/jama.2017.1282. PMID: 28418487.
Copy Download .nbib Format: NLM
Appendiceal spirochaetosis in children.

Gut pathogens

Westerman LJ, Schipper ME, Stel HV, Bonten MJ, Kusters JG.
PMID: 24330703
Gut Pathog. 2013 Dec 13;5(1):40. doi: 10.1186/1757-4749-5-40.

BACKGROUND: Acute appendicitis is a surgical emergency in which the appendix is surgically removed to prevent peritonitis due to perforation of the appendix. Depending on age and gender, up to 17% of removed appendices do not show the histopathological...

Cite
Westerman LJ, Schipper ME, Stel HV, et al. Appendiceal spirochaetosis in children. Gut Pathog. 2013;5(1):40doi: 10.1186/1757-4749-5-40.
Westerman, L. J., Schipper, M. E., Stel, H. V., Bonten, M. J., & Kusters, J. G. (2013). Appendiceal spirochaetosis in children. Gut pathogens, 5(1), 40. https://doi.org/10.1186/1757-4749-5-40
Westerman, Laurens J, et al. "Appendiceal spirochaetosis in children." Gut pathogens vol. 5,1 (2013): 40. doi: https://doi.org/10.1186/1757-4749-5-40
Westerman LJ, Schipper ME, Stel HV, Bonten MJ, Kusters JG. Appendiceal spirochaetosis in children. Gut Pathog. 2013 Dec 13;5(1):40. doi: 10.1186/1757-4749-5-40. PMID: 24330703; PMCID: PMC4029455.
Copy Download .nbib Format: NLM
Transmission of nosocomial pathogens.

The Netherlands journal of medicine

Bonten M.
PMID: 12430591
Neth J Med. 2002 Aug;60(7):52-4; discussion 54-7.

Prevention of the spread of antibiotic-resistant micro-organisms is one of the challenges for mankind in the new millennium, according to a recent report from the World Health Organization. In our Western world resistance problems occur mainly in intensive care...

Cite
Bonten M. Transmission of nosocomial pathogens. Neth J Med. 2002;60(7):52-4; discussion 54-7
Bonten, M. (2002). Transmission of nosocomial pathogens. The Netherlands journal of medicine, 60(7), 52-4; discussion 54-7.
Bonten, M. "Transmission of nosocomial pathogens." The Netherlands journal of medicine vol. 60,7 (2002): 52-4; discussion 54-7.
Bonten M. Transmission of nosocomial pathogens. Neth J Med. 2002 Aug;60(7):52-4; discussion 54-7. PMID: 12430591.
Copy Download .nbib Format: NLM
[Infection prevention in Dutch hospitals; results say more than process indicators].

Nederlands tijdschrift voor geneeskunde

Bonten MJ, Friedrich A, Kluytmans JA, Vandenbroucke-Grauls CM, Voss A, Vos MC.
PMID: 24594133
Ned Tijdschr Geneeskd. 2014;158:A7395.

The Dutch Health Care Inspectorate investigated the preparedness of Dutch hospitals for the emergence of antibiotic resistance, and concluded that hospitals are not well prepared and are insufficiently aware that infection prevention is a prerequisite for patient safety. These...

Cite
Bonten MJ, Friedrich A, Kluytmans JA, et al. Infectiepreventie in Nederlandse ziekenhuizen; resultaten zeggen meer dan procesindicatoren. [Infection prevention in Dutch hospitals; results say more than process indicators]. Ned Tijdschr Geneeskd. 2014;158:A7395
Bonten, M. J., Friedrich, A., Kluytmans, J. A., Vandenbroucke-Grauls, C. M., Voss, A., & Vos, M. C. (2014). Infectiepreventie in Nederlandse ziekenhuizen; resultaten zeggen meer dan procesindicatoren. [Infection prevention in Dutch hospitals; results say more than process indicators]. Nederlands tijdschrift voor geneeskunde, 158A7395.
Bonten, Marc J M, et al. "Infectiepreventie in Nederlandse ziekenhuizen; resultaten zeggen meer dan procesindicatoren." [Infection prevention in Dutch hospitals; results say more than process indicators]. Nederlands tijdschrift voor geneeskunde vol. 158 (2014): A7395.
Bonten MJ, Friedrich A, Kluytmans JA, Vandenbroucke-Grauls CM, Voss A, Vos MC. Infectiepreventie in Nederlandse ziekenhuizen; resultaten zeggen meer dan procesindicatoren. [Infection prevention in Dutch hospitals; results say more than process indicators]. Ned Tijdschr Geneeskd. 2014;158:A7395. Dutch. PMID: 24594133.
Copy Download .nbib Format: NLM
Individual differences in change blindness are predicted by the strength and stability of visual representations.

Neuroscience of consciousness

Andermane N, Bosten JM, Seth AK, Ward J.
PMID: 30697440
Neurosci Conscious. 2019 Jan 24;2019(1):niy010. doi: 10.1093/nc/niy010. eCollection 2019.

The phenomenon of change blindness reveals that people are surprisingly poor at detecting unexpected visual changes; however, research on individual differences in detection ability is scarce. Predictive processing accounts of visual perception suggest that better change detection may be...

Cite
Andermane N, Bosten JM, Seth AK, et al. Individual differences in change blindness are predicted by the strength and stability of visual representations. Neurosci Conscious. 2019;2019(1):niy010doi: 10.1093/nc/niy010.
Andermane, N., Bosten, J. M., Seth, A. K., & Ward, J. (2019). Individual differences in change blindness are predicted by the strength and stability of visual representations. Neuroscience of consciousness, 2019(1), niy010. https://doi.org/10.1093/nc/niy010
Andermane, Nora, et al. "Individual differences in change blindness are predicted by the strength and stability of visual representations." Neuroscience of consciousness vol. 2019,1 (2019): niy010. doi: https://doi.org/10.1093/nc/niy010
Andermane N, Bosten JM, Seth AK, Ward J. Individual differences in change blindness are predicted by the strength and stability of visual representations. Neurosci Conscious. 2019 Jan 24;2019(1):niy010. doi: 10.1093/nc/niy010. eCollection 2019. PMID: 30697440; PMCID: PMC6345093.
Copy Download .nbib Format: NLM
An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Deelen JWT, Rottier WC, Giron Ortega JA, Rodriguez-Baño J, Harbarth S, Tacconelli E, Jacobsson G, Zahar JR, van Werkhoven CH, Bonten MJM.
PMID: 32640024
Clin Infect Dis. 2021 Dec 06;73(11):e4475-e4483. doi: 10.1093/cid/ciaa950.

BACKGROUND: The possibility of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacterales (3GC-R-BSI) leads to a trade-off between empiric inappropriate treatment (IAT) and unnecessary carbapenem use (UCU). Accurately predicting 3GC-R-BSI could reduce IAT and UCU. We externally validate 2 previously...

Cite
Deelen JWT, Rottier WC, Giron Ortega JA, et al. An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. Clin Infect Dis. 2021;73(11):e4475-e4483doi: 10.1093/cid/ciaa950.
Deelen, J. W. T., Rottier, W. C., Giron Ortega, J. A., Rodriguez-Baño, J., Harbarth, S., Tacconelli, E., Jacobsson, G., Zahar, J. R., van Werkhoven, C. H., Bonten, M. J. M. (2021). An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(11), e4475-e4483. https://doi.org/10.1093/cid/ciaa950
Deelen, J W Timotëus, et al. "An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 73,11 (2021): e4475-e4483. doi: https://doi.org/10.1093/cid/ciaa950
Deelen JWT, Rottier WC, Giron Ortega JA, Rodriguez-Baño J, Harbarth S, Tacconelli E, Jacobsson G, Zahar JR, van Werkhoven CH, Bonten MJM. An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. Clin Infect Dis. 2021 Dec 06;73(11):e4475-e4483. doi: 10.1093/cid/ciaa950. PMID: 32640024.
Copy Download .nbib Format: NLM
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

The Lancet. Infectious diseases

Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L.
PMID: 34826381
Lancet Infect Dis. 2021 Nov 23; doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23.

BACKGROUND: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate.METHODS: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted...

Cite
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2021;doi: 10.1016/S1473-3099(21)00677-0.
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., Garcia Lopez, C. A., Gonzales, L., Granados González, M. A., Gorini, N., Grobusch, M. P., Hrabar, A. D., Junker, H., Kimura, A., Lanata, C. F., Lehmann, C., Leroux-Roels, I., Mann, P., Martinez-Reséndez, M. F., Ochoa, T. J., Poy, C. A., Reyes Fentanes, M. J., Rivera Mejia, L. M., Ruiz Herrera, V. V., Sáez-Llorens, X., Schönborn-Kellenberger, O., Schunk, M., Sierra Garcia, A., Vergara, I., Verstraeten, T., Vico, M., Oostvogels, L. (2021). Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. The Lancet. Infectious diseases, . https://doi.org/10.1016/S1473-3099(21)00677-0
Kremsner, Peter G, et al. "Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial." The Lancet. Infectious diseases vol. (2021). doi: https://doi.org/10.1016/S1473-3099(21)00677-0
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2021 Nov 23; doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23. PMID: 34826381; PMCID: PMC8610426.
Copy Download .nbib Format: NLM
Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study.

Shock (Augusta, Ga.)

Juschten J, Bos LDJ, de Grooth HJ, Beuers U, Girbes ARJ, Juffermans NP, Loer SA, van der Poll T, Cremer OL, Bonten MJM, Schultz MJ, Tuinman PR.
PMID: 34238904
Shock. 2022 Feb 01;57(2):161-167. doi: 10.1097/SHK.0000000000001836.

OBJECTIVE: To investigate the incidence, clinical characteristics and outcomes of early hyperbilirubinemia in critically ill patients.DESIGN AND SETTING: This is a post hoc analysis of a prospective multicenter cohort study.PATIENTS: Patients with measured bilirubin levels within the first 2...

Cite
Juschten J, Bos LDJ, de Grooth HJ, et al. Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study. Shock. 2022;57(2):161-167doi: 10.1097/SHK.0000000000001836.
Juschten, J., Bos, L. D. J., de Grooth, H. J., Beuers, U., Girbes, A. R. J., Juffermans, N. P., Loer, S. A., van der Poll, T., Cremer, O. L., Bonten, M. J. M., Schultz, M. J., Tuinman, P. R. (2022). Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study. Shock (Augusta, Ga.), 57(2), 161-167. https://doi.org/10.1097/SHK.0000000000001836
Juschten, Jenny, et al. "Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study." Shock (Augusta, Ga.) vol. 57,2 (2022): 161-167. doi: https://doi.org/10.1097/SHK.0000000000001836
Juschten J, Bos LDJ, de Grooth HJ, Beuers U, Girbes ARJ, Juffermans NP, Loer SA, van der Poll T, Cremer OL, Bonten MJM, Schultz MJ, Tuinman PR. Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study. Shock. 2022 Feb 01;57(2):161-167. doi: 10.1097/SHK.0000000000001836. PMID: 34238904.
Copy Download .nbib Format: NLM
Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study.

Intensive care medicine

Peters-Sengers H, Butler JM, Uhel F, Schultz MJ, Bonten MJ, Cremer OL, Scicluna BP, van Vught LA, van der Poll T.
PMID: 34902047
Intensive Care Med. 2021 Dec 13; doi: 10.1007/s00134-021-06574-0. Epub 2021 Dec 13.

PURPOSE: There is limited knowledge on how the source of infection impacts the host response to sepsis. We aimed to compare the host response in sepsis patients with a single, known source at admission (

Cite
Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2021;doi: 10.1007/s00134-021-06574-0.
Peters-Sengers, H., Butler, J. M., Uhel, F., Schultz, M. J., Bonten, M. J., Cremer, O. L., Scicluna, B. P., van Vught, L. A., van der Poll, T. (2021). Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive care medicine, . https://doi.org/10.1007/s00134-021-06574-0
Peters-Sengers, Hessel, et al. "Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study." Intensive care medicine vol. (2021). doi: https://doi.org/10.1007/s00134-021-06574-0
Peters-Sengers H, Butler JM, Uhel F, Schultz MJ, Bonten MJ, Cremer OL, Scicluna BP, van Vught LA, van der Poll T. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2021 Dec 13; doi: 10.1007/s00134-021-06574-0. Epub 2021 Dec 13. PMID: 34902047.
Copy Download .nbib Format: NLM
Erratum for Janssen et al., "Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics".

Antimicrobial agents and chemotherapy

Janssen AB, Doorduijn DJ, Mills G, Rogers MRC, Bonten MJM, Rooijakkers SHM, Willems RJL, Bengoechea JA, van Schaik W.
PMID: 34137639
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0075421. doi: 10.1128/AAC.00754-21. Epub 2021 Jun 17.

No abstract available.

Cite
Janssen AB, Doorduijn DJ, Mills G, et al. Erratum for Janssen et al., "Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics". Antimicrob Agents Chemother. 2021;65(7):e0075421doi: 10.1128/AAC.00754-21.
Janssen, A. B., Doorduijn, D. J., Mills, G., Rogers, M. R. C., Bonten, M. J. M., Rooijakkers, S. H. M., Willems, R. J. L., Bengoechea, J. A., & van Schaik, W. (2021). Erratum for Janssen et al., "Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics". Antimicrobial agents and chemotherapy, 65(7), e0075421. https://doi.org/10.1128/AAC.00754-21
Janssen, Axel B, et al. "Erratum for Janssen et al., "Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics"." Antimicrobial agents and chemotherapy vol. 65,7 (2021): e0075421. doi: https://doi.org/10.1128/AAC.00754-21
Janssen AB, Doorduijn DJ, Mills G, Rogers MRC, Bonten MJM, Rooijakkers SHM, Willems RJL, Bengoechea JA, van Schaik W. Erratum for Janssen et al., "Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics". Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0075421. doi: 10.1128/AAC.00754-21. Epub 2021 Jun 17. PMID: 34137639; PMCID: PMC8218661.
Copy Download .nbib Format: NLM
Human plasma IgG1 repertoires are simple, unique, and dynamic.

Cell systems

Bondt A, Hoek M, Tamara S, de Graaf B, Peng W, Schulte D, van Rijswijck DMH, den Boer MA, Greisch JF, Varkila MRJ, Snijder J, Cremer OL, Bonten MJM, Heck AJR.
PMID: 34613904
Cell Syst. 2021 Dec 15;12(12):1131-1143.e5. doi: 10.1016/j.cels.2021.08.008. Epub 2021 Sep 17.

Although humans can produce billions of IgG1 variants through recombination and hypermutation, the diversity of IgG1 clones circulating in human blood plasma has largely eluded direct characterization. Here, we combined several mass-spectrometry-based approaches to reveal that the circulating IgG1...

Cite
Bondt A, Hoek M, Tamara S, et al. Human plasma IgG1 repertoires are simple, unique, and dynamic. Cell Syst. 2021;12(12):1131-1143.e5doi: 10.1016/j.cels.2021.08.008.
Bondt, A., Hoek, M., Tamara, S., de Graaf, B., Peng, W., Schulte, D., van Rijswijck, D. M. H., den Boer, M. A., Greisch, J. F., Varkila, M. R. J., Snijder, J., Cremer, O. L., Bonten, M. J. M., & Heck, A. J. R. (2021). Human plasma IgG1 repertoires are simple, unique, and dynamic. Cell systems, 12(12), 1131-1143.e5. https://doi.org/10.1016/j.cels.2021.08.008
Bondt, Albert, et al. "Human plasma IgG1 repertoires are simple, unique, and dynamic." Cell systems vol. 12,12 (2021): 1131-1143.e5. doi: https://doi.org/10.1016/j.cels.2021.08.008
Bondt A, Hoek M, Tamara S, de Graaf B, Peng W, Schulte D, van Rijswijck DMH, den Boer MA, Greisch JF, Varkila MRJ, Snijder J, Cremer OL, Bonten MJM, Heck AJR. Human plasma IgG1 repertoires are simple, unique, and dynamic. Cell Syst. 2021 Dec 15;12(12):1131-1143.e5. doi: 10.1016/j.cels.2021.08.008. Epub 2021 Sep 17. PMID: 34613904.
Copy Download .nbib Format: NLM
Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients.

Clinical and translational science

Lucafò M, Granata S, Bonten EJ, McCorkle R, Stocco G, Caletti C, Selvestrel D, Cozzarolo A, Zou C, Cuzzoni E, Pasini A, Montini G, Gambaro G, Decorti G, Evans W, Zaza G.
PMID: 33382913
Clin Transl Sci. 2021 May;14(3):964-975. doi: 10.1111/cts.12961. Epub 2021 Jan 25.

To assess whether NLRP3 gene promoter methylation was able to discriminate glucocorticoid (GC)-resistant from GC-sensitive idiopathic nephrotic syndrome (INS), patients with minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), we measured the methylation level of NLRP3 promoter in...

Cite
Lucafò M, Granata S, Bonten EJ, et al. Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. Clin Transl Sci. 2021;14(3):964-975doi: 10.1111/cts.12961.
Lucafò, M., Granata, S., Bonten, E. J., McCorkle, R., Stocco, G., Caletti, C., Selvestrel, D., Cozzarolo, A., Zou, C., Cuzzoni, E., Pasini, A., Montini, G., Gambaro, G., Decorti, G., Evans, W., & Zaza, G. (2021). Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. Clinical and translational science, 14(3), 964-975. https://doi.org/10.1111/cts.12961
Lucafò, Marianna, et al. "Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients." Clinical and translational science vol. 14,3 (2021): 964-975. doi: https://doi.org/10.1111/cts.12961
Lucafò M, Granata S, Bonten EJ, McCorkle R, Stocco G, Caletti C, Selvestrel D, Cozzarolo A, Zou C, Cuzzoni E, Pasini A, Montini G, Gambaro G, Decorti G, Evans W, Zaza G. Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. Clin Transl Sci. 2021 May;14(3):964-975. doi: 10.1111/cts.12961. Epub 2021 Jan 25. PMID: 33382913; PMCID: PMC8212736.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries